COX inhibitors have been shown to reduce the occurrence of cancers and pre-cancerous growths.

Ketorolac is a non selective COX inhibitor.

The main COX inhibitors are the non-steroidal anti-inflammatory drugs (NSAIDs).

The classical COX inhibitors are not selective and inhibit all types of COX.

Indomethacin, therefore, like other non-selective COX inhibitors can cause peptic ulcers.

The adverse effects of COX 2 inhibitors are the subject of extensive scientific debate.

It is not considered an NSAID because it does not exhibit significant anti-inflammatory activity (it is a weak COX inhibitor).

TXA is involved in activating other platelets and its formation is inhibited by COX inhibitors, such as aspirin.

Promising results have already been attained in animal models using COX inhibitors as co-therapies in the treatment of colorectal cancer and present a valuable future research direction.

Thus IDO expression does not mimic the effects of a global COX inhibitor.